Gracell Biotechnologies, Inc. (GRCL)

NASDAQ: GRCL · Delayed Price · USD
3.32
-0.17 (-4.87%)
At close: Jan 27, 2022 4:00 PM
3.29
-0.03 (-0.90%)
After-hours:Jan 27, 2022 4:00 PM EST
Market Cap224.10M
Revenue (ttm)n/a
Net Income (ttm)-443.43M
Shares Out67.50M
EPS (ttm)-1.25
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume262,095
Open3.57
Previous Close3.49
Day's Range3.20 - 3.64
52-Week Range3.20 - 33.70
Betan/a
AnalystsStrong Buy
Price Target33.33 (+903.9%)
Earnings Daten/a

About GRCL

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (...

IndustryBiotechnology
IPO DateJan 8, 2021
Employees202
Stock ExchangeNASDAQ
Ticker SymbolGRCL
Full Company Profile

Financial Performance

Financial numbers in millions CNYFinancial Statements

Analyst Forecast

According to 3 analysts, the average rating for GRCL stock is "Strong Buy." The 12-month stock price forecast is 33.33, which is an increase of 903.92% from the latest price.

Price Target
$33.33
(903.92% upside)
Analyst Consensus: Strong Buy

News

Gracell Biotechnologies to Participate in B Riley Securities 2022 Virtual Oncology Conference

SUZHOU, China and PALO ALTO, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering...

1 week ago - GlobeNewsWire

Gracell Biotechnologies Unveils Innovation Center in U.S.

SUZHOU, China and PALO ALTO, Calif. , Jan. 12, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated ...

2 weeks ago - PRNewsWire

Gracell Biotechnologies Selected for Addition to NASDAQ Biotechnology Index

SUZHOU and SHANGHAI, China, and PALO ALTO, Calif., Dec. 16, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical compa...

Other symbols:IBB
1 month ago - PRNewsWire

Gracell Biotechnologies Announces Senior Management Team Share Purchase Plan

SUZHOU, China and PALO ALTO, Calif., Nov. 23, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated t...

2 months ago - PRNewsWire

Gracell Biotechnologies Granted FDA Orphan Drug Designation for FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell T...

SUZHOU and SHANGHAI, China, and PALO ALTO, Calif., Nov. 19, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to d...

2 months ago - PRNewsWire

Gracell Biotechnologies to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

SUZHOU, China and PALO ALTO, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering...

2 months ago - GlobeNewsWire

Gracell Biotechnologies Reports Third Quarter 2021 Unaudited Financial Results and Provides Corporate Update

SUZHOU, China and PALO ALTO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering...

2 months ago - GlobeNewsWire

Gracell Biotechnologies to Present Preclinical Results of TruUCAR-enabled CD19/CD7 Dual-Directed Allogeneic CAR-T Cel...

SUZHOU and SHANGHAI, China, and PALO ALTO, California, Nov. 4, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated t...

2 months ago - PRNewsWire

Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences

SUZHOU, China and PALO ALTO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering...

2 months ago - GlobeNewsWire

Gracell Biotechnologies to Participate in Two Upcoming Virtual Investor Conferences

SUZHOU, China and PALO ALTO, Calif., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering...

3 months ago - GlobeNewsWire

Gracell Biotechnologies to Participate in Upcoming Virtual Investor Conferences in September

SUZHOU, China and PALO ALTO, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering...

5 months ago - GlobeNewsWire

Gracell Biotechnologies Reports Second Quarter 2021 Unaudited Financial Results and Provides Corporate Update

SUZHOU, China and PALO ALTO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering...

5 months ago - GlobeNewsWire

Gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell T...

SUZHOU and SHANGHAI, China, and PALO ALTO, Calif., Aug. 16, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to d...

5 months ago - PRNewsWire

Gracell Biotechnologies to Participate in Fireside Chat at the BTIG Virtual Biotechnology Conference

SUZHOU, China and PALO ALTO, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering...

6 months ago - GlobeNewsWire

All You Need to Know About Gracell Biotechnologies Inc. Sponsored ADR (GRCL) Rating Upgrade to Buy

Gracell Biotechnologies Inc. Sponsored ADR (GRCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

6 months ago - Zacks Investment Research

Gracell Biotechnologies Reschedules Clinical Update Conference Call and Webcast to June 14, 2021

SUZHOU, China and PALO ALTO, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering...

7 months ago - GlobeNewsWire

Gracell Biotechnologies Hosting Key Opinion Leader Webinar on High Risk Multiple Myeloma, Treatment Challenges and Du...

SUZHOU, China and PALO ALTO, Calif., May 26, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and ...

8 months ago - PRNewsWire

Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in June

SUZHOU, China and PALO ALTO, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering ...

8 months ago - GlobeNewsWire

Gracell Biotechnologies to Host Clinical Update Conference Call and Webcast on June 4, 2021 at 11:00am EDT

SUZHOU, China and PALO ALTO, Calif., May 21, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering ...

8 months ago - GlobeNewsWire

Gracell Biotechnologies to Present Updated Results of GC012F FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Ther...

SUZHOU, China and PALO ALTO, Calif. , May 19, 2021 /PRNewswire/ --  Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing hig...

8 months ago - PRNewsWire

Gracell Biotechnologies Reports First Quarter 2021 Unaudited Financial Results and Provides Corporate Update

Reported updated long-term follow-up data for TruUCAR-enabled CD7-targeted CAR-T product candidate GC027 for the treatment of T-ALL at AACR 2021 Annual Meeting

8 months ago - GlobeNewsWire

Gracell Biotechnologies Appoints Seasoned Gene & Cell Therapy Executive Dr. Jenny (Yajin) Ni as Chief Technology Officer

SUZHOU and SHANGHAI, China, May 10, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficac...

8 months ago - PRNewsWire

Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in May

SUZHOU and SHANGHAI, China, April 30, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and dev...

8 months ago - GlobeNewsWire

Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2020

SUZHOU and SHANGHAI, China, April 23, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly e...

9 months ago - GlobeNewsWire

Gracell Biotechnologies Reports Long-term Follow-up Data on TruUCAR-enabled GC027 in Relapsed/Refractory T-ALL at the...

SUZHOU and SHANGHAI, China, April 10, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly effic...

9 months ago - PRNewsWire